Pros | - | ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | - | 8/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 3 Years | 5 Years | ||
Fund Size | 214 Cr | 815 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹1000 | ||
Expense Ratio | 0.47% | 1.1% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 29 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (16.22%) Divi's Laboratories Ltd (5.96%) Lupin Ltd (5.78%) Suven Pharmaceuticals Ltd (5.39%) Apollo Hospitals Enterprise Ltd (5.16%) | Sun Pharmaceuticals Industries Ltd (14.49%) Cipla Ltd (8.9%) Torrent Pharmaceuticals Ltd (7.6%) Abbott India Ltd (6.56%) Apollo Hospitals Enterprise Ltd (5.93%) | ||
No of Sectors | 3 | 2 | ||
Top 3 Sectors | Health (95.43%) Basic Materials (3.54%) Industrial (1.03%) | Health (99.2%) Basic Materials (0.8%) | ||
Equity % | 97.95% | 98.62% | ||
Debt % | - | - | ||
P/E | 37.64 | 35.29 | ||
P/B | 5.87 | 5.9 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 5.7% | 4.95% | ||
3-Month Return | -3.15% | -1.82% | ||
6-Month Return | -6.09% | -7.08% | ||
1-Year Return | 18.55% | 15.62% | ||
3-Year Return | 20.04% | 18.69% | ||
5-Year Return | - | 21.61% |
Sharpe | 0.84 | 0.74 | ||
Alpha | 2.89 | -0.56 | ||
Beta | 0.91 | 0.96 | ||
Standard Deviation | 16.41 | 16.88 | ||
Information Ratio | 0.51 | -0.34 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Dhaval Shah |